A citation-based method for searching scientific literature

Melanie J Davies, David A D'Alessio, Judith Fradkin, Walter N Kernan, Chantal Mathieu, Geltrude Mingrone, Peter Rossing, Apostolos Tsapas, Deborah J Wexler, John B Buse. Diabetes Care 2018
Times Cited: 991



Vlado Perkovic, Meg J Jardine, Bruce Neal, Severine Bompoint, Hiddo J L Heerspink, David M Charytan, Robert Edwards, Rajiv Agarwal, George Bakris, Scott Bull, Christopher P Cannon, George Capuano, Pei-Ling Chu, Dick de Zeeuw, Tom Greene, Adeera Levin, Carol Pollock, David C Wheeler, Yshai Yavin, Hong Zhang, Bernard Zinman, Gary Meininger, Barry M Brenner, Kenneth W Mahaffey. N Engl J Med 2019
Times Cited: 1381




List of shared articles



Times cited

A Pilot Study Embedding Clinical Pharmacists Within an Interprofessional Nephrology Clinic for the Initiation and Monitoring of Empagliflozin in Diabetic Kidney Disease.
Laura K Triantafylidis, Chelsea E Hawley, Christopher Fagbote, Jiahua Li, Nicole Genovese, Julie M Paik. J Pharm Pract 2021
5


Safety and effectiveness of tofogliflozin in Japanese patients with type 2 diabetes mellitus treated in real-world clinical practice: Results of a 36-month post-marketing surveillance study (J-STEP/LT).
Kazunori Utsunomiya, Ryusuke Koshida, Seigo Kakiuchi, Masayuki Senda, Shoko Fujii, Yuji Kurihara, Ryoji Gunji, Kohei Kaku. J Diabetes Investig 2021
0

SGLT-2 inhibitors and nephroprotection: current evidence and future perspectives.
Alexia Piperidou, Charalampos Loutradis, Pantelis Sarafidis. J Hum Hypertens 2021
1

Management of post-transplant diabetes: immunosuppression, early prevention, and novel antidiabetics.
Manfred Hecking, Adnan Sharif, Kathrin Eller, Trond Jenssen. Transpl Int 2021
5

Guideline recommendations and the positioning of newer drugs in type 2 diabetes care.
Nikolaus Marx, Melanie J Davies, Peter J Grant, Chantal Mathieu, John R Petrie, Francesco Cosentino, John B Buse. Lancet Diabetes Endocrinol 2021
10

Diabetes Management in Chronic Kidney Disease: Synopsis of the 2020 KDIGO Clinical Practice Guideline.
Sankar D Navaneethan, Sophia Zoungas, M Luiza Caramori, Juliana C N Chan, Hiddo J L Heerspink, Clint Hurst, Adrian Liew, Erin D Michos, Wasiu A Olowu, Tami Sadusky,[...]. Ann Intern Med 2021
8

SGLT2-inhibitors; more than just glycosuria and diuresis.
Amir Fathi, Keeran Vickneson, Jagdeep S Singh. Heart Fail Rev 2021
3

The cost-effectiveness of dapagliflozin in treating high-risk patients with type 2 diabetes mellitus: An economic evaluation using data from the DECLARE-TIMI 58 trial.
Phil McEwan, Angharad R Morgan, Rebecca Boyce, Klas Bergenheim, Ingrid A M Gause-Nilsson, Deepak L Bhatt, Lawrence A Leiter, Peter A Johansson, Ofri Mosenzon, Avivit Cahn,[...]. Diabetes Obes Metab 2021
4

Effects of intensive exercise combined with dapagliflozin on body composition in patients with type 2 diabetes: a randomized controlled trial.
Ryotaro Bouchi, Noriyuki Sonoda, Jun Itoh, Yasuhiro Ono, Tatsuya Fukuda, Takato Takeuchi, Junji Kishimoto, Tetsuya Yamada, Yoshihiro Ogawa. Endocr J 2021
0

Systematic review and meta-analysis: SGLT2 inhibitors, blood pressure and cardiovascular outcomes.
Jamie L Benham, Jane E Booth, Ronald J Sigal, Stella S Daskalopoulou, Alexander A Leung, Doreen M Rabi. Int J Cardiol Heart Vasc 2021
0

Oral Semaglutide Reduces HbA1c and Body Weight in Patients with Type 2 Diabetes Regardless of Background Glucose-Lowering Medication: PIONEER Subgroup Analyses.
Richard E Pratley, Matthew J Crowley, Mette Gislum, Christin L Hertz, Thomas B Jensen, Kamlesh Khunti, Ofri Mosenzon, John B Buse. Diabetes Ther 2021
1



From glucose lowering agents to disease/diabetes modifying drugs: a "SIMPLE" approach for the treatment of type 2 diabetes.
Ofri Mosenzon, Stefano Del Prato, Meir Schechter, Lawrence A Leiter, Antonio Ceriello, Ralph A DeFronzo, Itamar Raz. Cardiovasc Diabetol 2021
1

SGLT2is and Renal Protection: From Biological Mechanisms to Real-World Clinical Benefits.
Giovanna Leoncini, Elisa Russo, Elisabetta Bussalino, Cecilia Barnini, Francesca Viazzi, Roberto Pontremoli. Int J Mol Sci 2021
0